CLNNW Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 16:00):

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics...

Stats
Today's Volume	1 200.00
Average Volume	0.00
Market Cap	42.25M
EPS	$-0.000290 ( 2023-06-29 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2023-11-28	Desai Arjun Jj	Buy	33 040	Stock Options (Right to buy)
2023-11-28	Jacobovitz Shalom	Buy	42 736	Stock Options (Right to buy)
2023-11-28	Matlin David J	Buy	56 024	Stock Options (Right to buy)
2023-11-28	Kiernan Matthew	Buy	28 730	Stock Options (Right to buy)
2023-11-28	Mosca Alison	Buy	43 814	Stock Options (Right to buy)

INSIDER POWER
99.47
Last 99 transactions
Buy: 47 544 964 \| Sell: 666 194

Clene Inc. Correlation

10 Most Positive Correlations
HDL	0.922
RAY	0.918

10 Most Negative Correlations
BOTT	-0.804

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Clene Inc. Financials

Annual	2023
Revenue:	$654 000
Gross Profit:	$-1.17M (-179.20 %)
EPS:	$-0.470

FY	2023
Revenue:	$654 000
Gross Profit:	$-1.17M (-179.20 %)
EPS:	$-0.470

FY	2022
Revenue:	$473 000
Gross Profit:	$447 000 (94.50 %)
EPS:	$-0.230

FY	2021
Revenue:	$723 000
Gross Profit:	$434 000 (60.03 %)
EPS:	$0

Financial Reports:

No articles found.

Clene Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Clene Inc.

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain\'s energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson\'s Diseases. The company\'s products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.